The primary objective of this study was to evaluate the safety and effectiveness of the Mirage bioresorbable microfiber sirolimus-eluting scaffold compared with the Absorb bioresorbable vascular scaffold in the treatment of stenotic target lesions located in native coronary arteries, ranging from $2.25 to #4.0 mm in diameter.
Currently the existing limitations are 1) low tensile and radial strength, necessitating thick struts to prevent acute recoil; 2) insufficient ductility, which affects scaffold crimping and retention on the delivery balloon and limits the range of scaffold expansion during deployment; and 3) early mechanical disruption or late structural discontinuity of the struts inherent to the polymer used and its elongation at break and resorption decay. In other words, the optimal performance goal and the mechanical dilemma with BRS is to obtain high tensile strength combined with ductility and high elongation at break (1) .
Polylactide and poly(D,L-lactide) have tensile strengths ranging between 45 and 70 MPa, with an elongation at break of 2% to 6%, whereas cobalt chromium has a tensile strength of 1,449 MPa and an elongation at break of 40% (2) . Currently, polymer experts test the complex composition of polymers, mixing polylactide, polyglycolide, and polycaprolactone to alter mechanical properties and to achieve radial strength and ductility that could be comparable at least with stainless steel stents.
Another way to modify the mechanical properties of the polylactide is to intervene on the molecular orientation of the polymer by using proprietary manufacturing processes that involve stretching (melt extrusion, drawing) and temperature alteration The secondary objectives of this study were to establish the medium-term safety, effectiveness, and performance of the Mirage BRMS, assessed at multiple time points, through assessment of clinical, angiographic, and optical coherence tomographic (OCT) data.
METHODS DESCRIPTION OF THE DEVICE.
The Mirage is a poly-L-lactic acid-based scaffold with <5% of dextrorotary isomer of polylactic acid. As described in the introduction, the device has a helicoid structure, which provides high flexibility. The strut thickness for a scaffold with a diameter #3 mm is 125 mm, whereas scaffolds with diameters >3 mm have a strut thickness of 150 mm. The aim of this new technology is not only to reduce strut thickness but also to increase the embedment of the struts. Because of the round shape of the struts, it will be more easy to embed the struts into the vessel wall, thereby reducing disturbance of flow (3). The vessel coverage ratio is high, about 40% to 47%, compared with 27% for the Absorb BVS. The device is available with diameters of 2.5, 2.75, 3.0, 3.5, and 4.0 mm and lengths of 18, 28, and 38 mm.
The crossing profile of the smallest device (2.5 mm) is scaffold with strut thickness of 125 mm has a tensile strength of 300 MPa with an elongation at break of 35% and a radial strength of 120 kPa, very comparable with the radial strength of the XIENCE V for a strut thickness of 81 mm. BRMS ¼ sirolimus-eluting bioresorbable microfiber scaffold; MW ¼ molecular weight.
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Emerging Bioresorbable Scaffolds function of inflation pressure are reported in Online In vitro and in vivo degradation profile confirms that the Mirage polylactide is basically fully biodegraded after 14 months.
Emerging Bioresorbable Scaffolds Table 2 ). Reference diameter and percentage DS were calculated using the interpolation method (9,10).
OCT IMAGING. All procedures were done under angiographic guidance. OCT imaging was performed only for documentary purposes. Post-procedural luminal areas (minimal, mean, and reference), luminal asymmetry and eccentricity, and strut coverage and apposition were assessed using OCT imaging. The scaffold expansion index was specifically defined as the ratio of minimal scaffold area divided by maximum reference luminal area (2) . Values are n/N (%). *Fisher exact test.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; LAD ¼ left anterior descending coronary artery; LCx ¼ left circumflex coronary artery; RCA ¼ right coronary artery.
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Emerging Bioresorbable Scaffolds -2 0 1 7 : ---variables are presented as counts and percentages.
Continuous variables were compared using the Values are mean AE SD or n/N (%). *A total of 34 lesions were included in the Mirage group. Three of these were treated with 2 overlapping scaffolds each. For the sake of this comparison, the scaffolds were computed separately, totaling 37 scaffolds. †Mann-Whitney U test. ‡Mean reference diameter is the average of the mean distal and proximal reference luminal diameters. §Chi-square test. ¶In cases in which post-dilatation was not performed, the nominal diameter of the delivery balloon was used.
BRMS ¼ sirolimus-eluting bioresorbable microfiber scaffold; BVS ¼ bioresorbable vascular scaffold; OCT ¼ optical coherence tomography.
Tenekecioglu et al. ( Table 5 ).
In particular, the in-scaffold minimal luminal area (MLA) post-procedure was identical in both groups. At Values are mean AE SD unless otherwise indicated. For luminal DS calculations, diameters were estimated as the diameter of a circle that has an equivalent area to the cross-sectional areas analyzed. *Related-samples Wilcoxon signed rank test. †LA stenosis (method 1): (mean reference luminal area À in-scaffold MLA/mean reference luminal area). ‡LA stenosis (method 2): (maximum reference luminal area À in-scaffold MLA/maximum reference luminal area). §Luminal DS (method 1): (mean reference luminal diameter À in-scaffold lumen diameter at MLA/mean reference luminal area). ¶Luminal DS (method 2): (maximum reference luminal diameter À in-scaffold luminal diameter at MLA/maximum reference luminal area).
LA ¼ luminal area; other abbreviations as in Tables 3 and 4 .
Emerging Bioresorbable Scaffolds -2 0 1 7 : ---borderline significance ( Table 6 ). Serial OCT measurements in the Absorb group showed a similar pattern of change, although the quantitative differences were numerically lower ( Table 7) . In patients without TLR, serial OCT measurements demonstrated comparable luminal DS in the Absorb and Mirage groups ( Figure 5 ).
CLINICAL OUTCOMES. Clinical events in the study groups are listed in Table 8 . Values are mean AE SD unless otherwise indicated. For luminal DS calculations, diameters were estimated as the diameter of a circle that has an equivalent area to the cross-sectional areas analyzed. *Related-samples Wilcoxon signed rank test. †Luminal area stenosis (method 1): (mean reference luminal area À in-scaffold MLA/mean reference luminal area). ‡Luminal area stenosis (method 2): (maximum reference lumen area À in-scaffold MLA/maximum reference luminal area). §Luminal DS (method 1): (mean reference luminal diameter À in-scaffold luminal diameter at MLA/mean reference luminal area). ¶Luminal DS (method 2): (maximum reference luminal diameter À in-scaffold lumen diameter at MLA/maximum reference luminal area). Tables 3 and 4 .
Abbreviations as in
Emerging Bioresorbable Scaffolds Values are n/N (%). The p values were calculated using the Fisher exact test. *In the Mirage arm, 2 patients were lost to follow-up without events (Patients #001-047 and #001-054). In the Absorb arm, 2 patients were lost to follow-up without events (Patients #001-053 and #001-061). †Patients #02-008 and #01-028 had both clinically indicated target lesion revascularization/target vessel revascularization and non-clinically indicated non-target-vessel revascularization.
The scaffold manufacturing process of wrapping a circular monofilament around a metallic rod allows a large variety of nominal device sizes (2.5 mm, 2.75 mm, 3.0 mm, etc.). Therefore, selection of precisely sized device should be made to treat vessels whose dimensions have been thoroughly investigated and sized using OCT imaging. Tenekecioglu et al.
